Buenos Aires - Delayed Quote ARS

Merck & Co., Inc. (MRK.BA)

28,471.00

+120.00

(+0.42%)

At close: 4:58 PM GMT-3

Merck (MRK) Q1 2024 Earnings Call Transcript

MRK earnings call for the period ending March 31, 2024.

Motley Fool yesterday

MRK
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook

On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me

Benzinga yesterday

MRK
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales

Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.

Zacks yesterday

MRK
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma

Bristol-Myers Squibb’s market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporting disappointing earnings figures on Thursday, the company’s shares fell sharply, giving it a market capitalization of about $95 billion. The problem for Bristol-Myers is that its older blockbuster products, cancer drug Revlimid and blood thinner Eliquis, are expected to decline in the coming years and investors aren’t convinced that the company has enough growth drivers in the near term.

The Wall Street Journal yesterday

REGN

PFE

BMY
20 Fastest Growing Health Tech Companies in the World

In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]

Insider Monkey yesterday

TDOC

SNY

GSK
Merck raises 2024 guidance on cancer drug demand

Shares of Merck & Company (MRK) are trading higher early Thursday after the pharmaceutical giant posted robust sales results in the first quarter, leading the pharmaceutical giant to raise its 2024 outlook. The company's performance was driven by strong demand for its cancer drug Keytruda. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance. This post was written by Angel Smith

Yahoo Finance Video yesterday

MRK
Merck Stock Climbs After Higher-Than-Expected Sales of Cancer Drug Keytruda

Shares of U.S. drugmaker Merck are up nearly 4% in recent trading after the company said its blockbuster cancer drug Keytruda fueled a higher-than-expected increase in quarterly sales and earnings. Merck also raised and narrowed its forecast range for full-year sales and earnings. Sales of Keytruda, the world’s top-selling drug, rose 20% to $6.9 billion for the first quarter.

The Wall Street Journal yesterday

MRK
We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Simply Wall St. yesterday

MRK
UPDATE 3-Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda

Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of double-digit growth for its blockbuster cancer drug Keytruda, the world's top selling prescription medicine. Merck forecast 2024 sales between $63.1 billion and $64.3 billion, up from its previous view of $62.7 billion to $64.2 billion. Analysts are estimating sales of $63.83 billion.

Reuters yesterday

MRK
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda

(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer drug Keytruda, sending the company's shares up more than 2% before the bell. Keytruda, the world's top selling drug in 2023, has been Merck's key revenue driver over the past few years and is expected to top $30 billion in sales by 2026 before losing exclusivity toward the end of the decade. The drug is seeing growth from use for additional types of cancers as well as higher patient demand, Chief Financial Officer Caroline Litchfield said.

Reuters yesterday

MRK
Merck Announces First-Quarter 2024 Financial Results

RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results

Business Wire yesterday

MRK
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales

Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil. The New Jersey-based drugmaker said it expected earnings of $8.53 and $8.65 per share, up from its previous prediction of $8.44 to $8.59, and sales of $63.1-$64.3 billion for the year. Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said.

Reuters yesterday

MRK
Alphabet, Microsoft, Southwest earnings: What to watch

Here are some of the biggest stories investors will be watching on Thursday, April 25, 2024. A slew of companies will report their quarterly results including Microsoft (MSFT), Alphabet (GOOG, GOOGL), and Southwest Airlines (LUV). On the economic data front, the highly anticipated preliminary read on first quarter GDP will be released. Economists are expecting that the US economy grew by 2.2% in the first three months of the year. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith

Yahoo Finance Video 2 days ago

CMCSA

TMUS

CAT
4 Large Drug Stocks to Hold on to Amid Industry Challenges

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

Zacks 2 days ago

ABBV

LLY

NVO
Here’s Why Merck & Co. (MRK) Outperformed in Q1

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]

Insider Monkey 3 days ago

MRK

^GSPC
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.

Zacks 4 days ago

MRK
10 Best Performing Biotech ETFs in 2024

In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]

Insider Monkey 4 days ago

LLY

EXAS

NBIX
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 78%

Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their...

Simply Wall St. 5 days ago

MRK
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval is based on the results from the Phase 3 KEYNOTE-859 trial, whic

CNW Group 7 days ago

MRK
13 Best Low Volatility Stocks to Buy According to Hedge Funds

In this article, we discuss the 13 best low volatility stocks to buy according to hedge funds. To skip the detailed analysis of the current market conditions, go directly to the 5 Best Low Volatility Stocks to Buy According to Hedge Funds. The S&P 500 had a remarkable year in 2023 and the first quarter […]

Insider Monkey 8 days ago

^GSPC

^VIX

TSM

Performance Overview

Return	MRK.BA	S&P 500
YTD	+34.49%	+6.92%
1-Year	+162.12%	+25.26%
3-Year	+1,097.16%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merck & Co., Inc. (MRK.BA)

Merck (MRK) Q1 2024 Earnings Call Transcript

Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook

Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales

Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma

20 Fastest Growing Health Tech Companies in the World

Merck raises 2024 guidance on cancer drug demand

Merck Stock Climbs After Higher-Than-Expected Sales of Cancer Drug Keytruda

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

UPDATE 3-Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda

Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda

Merck Announces First-Quarter 2024 Financial Results

Merck raises 2024 profit forecast on strong cancer, HPV drugs sales

Alphabet, Microsoft, Southwest earnings: What to watch

4 Large Drug Stocks to Hold on to Amid Industry Challenges

Here’s Why Merck & Co. (MRK) Outperformed in Q1

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

10 Best Performing Biotech ETFs in 2024

Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 78%

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy

13 Best Low Volatility Stocks to Buy According to Hedge Funds

Performance Overview